NASDAQ:TNXP Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis $2.38 -0.17 (-6.67%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$2.39 +0.01 (+0.25%) As of 11/20/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Tonix Pharmaceuticals Stock (NASDAQ:TNXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tonix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.30▼$2.6350-Day Range$2.38▼$11.7652-Week Range$2.30▼$20.56Volume1.26 million shsAverage Volume1.08 million shsMarket Capitalization$46.25 millionP/E RatioN/ADividend YieldN/APrice Target$22.33Consensus RatingBuy Company Overview Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox. Tonix is led by co-founder, chairman and chief executive officer Seth Lederman, M.D. Its operations and commercial focus are centered in the United States.AI Generated. May Contain Errors. Read More Tonix Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreTNXP MarketRank™: 3.553684210525 of 5 starsTonix Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 215th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingTonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialTonix Pharmaceuticals has a consensus price target of $22.33, representing about 838.4% upside from its current price of $2.38.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Tonix Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($10.73) to ($6.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.74% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently increased by 12.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.09 News SentimentTonix Pharmaceuticals has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest11 people have searched for TNXP on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows8 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $47,830.00 in company stock, which represents 0.1034% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,830.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.00% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by Institutions82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tonix Pharmaceuticals' insider trading history. Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNXP Stock News HeadlinesTNXP: Tonmya® Launch Continues to Build Momentum; 37% QoQ Growth in RevenueNovember 16, 2026 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Cut to Sell at Wall Street ZenNovember 14, 2026 | americanbankingnews.comWhoops! I wasn’t supposed to share this with you yetTraders have paid as much as $500 for technology like this. Thomas Wood of Base Camp Trading is offering his proprietary Snapback Indicator for just $7. There is no subscription and no recurring charge, and it's yours for life. The indicator is designed to help identify potential market turning points, showing when it may be time to buy, sell, or go short.November 22 at 1:00 AM | Base Camp Trading (Ad)Tonix Pharmaceuticals (NASDAQ:TNXP) Stock: Insider Seth Lederman Purchases 5,000 SharesNovember 13, 2026 | insidertrades.comTonix Pharmaceuticals (TNXP) Stock Fair Value Falls As Analysts Weigh Tonmya And Funding RiskNovember 12, 2026 | finance.yahoo.comTonix Pharmaceuticals Earnings Call Highlights TONMYA GrowthNovember 9, 2026 | tipranks.comTonix Pharmaceuticals Holding Corp (TNXP) Q3 2026 Earnings Call Highlights: Tonmya Sales Surge ...November 9, 2026 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Q3 2026 Earnings Call TranscriptNovember 9, 2026 | fool.comSee More Headlines TNXP Stock Analysis - Frequently Asked Questions How have TNXP shares performed this year? Tonix Pharmaceuticals' stock was trading at $15.62 at the beginning of the year. Since then, TNXP stock has decreased by 84.8% and is now trading at $2.38. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Monday, November, 9th. The company reported ($2.89) earnings per share for the quarter, missing analysts' consensus estimates of ($2.39) by $0.50. The firm had revenue of $17.23 million for the quarter, compared to analysts' expectations of $16.32 million. Tonix Pharmaceuticals had a negative trailing twelve-month return on equity of 80.97% and a negative net margin of 420.45%. Read the conference call transcript. When did Tonix Pharmaceuticals' stock split? Tonix Pharmaceuticals's stock reverse split before market open on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tonix Pharmaceuticals' major shareholders? Top institutional investors of Tonix Pharmaceuticals include Logos Global Management LP (2.83%), State Street Corp (1.72%), Goldman Sachs Group Inc. (0.54%) and Ieq Capital LLC (0.36%). Insiders that own company stock include Seth Lederman, Richard Newcomb Stillwell, Carolyn E Taylor and Richard H Bagger. View institutional ownership trends. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD), Ocugen (OCGN) and SNDL (SNDL). Company Calendar Last Earnings11/09/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TNXP's financial health is in the Red zone, according to TradeSmith. TNXP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TNXP CIK1430306 Webwww.tonixpharma.com Phone(862) 799-8599Fax212-923-5700Employees142Year Founded2007Price Target and Rating Average Price Target for Tonix Pharmaceuticals$22.33 High Price Target$27.00 Low Price Target$18.00 Potential Upside/Downside+838.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($12.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.02 million Net Margins-420.45% Pretax Margin-420.45% Return on Equity-80.97% Return on Assets-70.18% Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.47 Sales & Book Value Annual Sales$43.05 million Price / Sales1.07 Cash FlowN/A Price / Cash FlowN/A Book Value$10.27 per share Price / Book0.23Miscellaneous Outstanding Shares19,432,000Free Float19,043,000Market Cap$46.25 million OptionableOptionable Beta1.90 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TNXP) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.